{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:56:05Z","timestamp":1769831765057,"version":"3.49.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dr. Miura Masatomo (Department of Pharmacy, Akita University Hospital, Akita, Japan)"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.lungcan.2016.07.008","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T18:08:57Z","timestamp":1467914937000},"page":"120-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-9138","authenticated-orcid":false,"given":"Yoshihiko","family":"Sakata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodai","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Shingu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Ichikado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.07.008_bib0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.lungcan.2013.08.004","article-title":"Identification of subgroup patients with stage IIIB\/IV non-small cell lung cancer at higher risk for brain metastases","volume":"82","author":"Hsiao","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.07.008_bib0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.lungcan.2013.02.004","article-title":"CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives","volume":"80","author":"Berger","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.07.008_bib0015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.lungcan.2016.07.008_bib0020","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.07.008_bib0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.bjc.6601953","article-title":"Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value","volume":"91","author":"Herrlinger","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.07.008_bib0030","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","article-title":"Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study","volume":"21","author":"Besse","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.07.008_bib0035","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2016.07.008_bib0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","article-title":"Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer","volume":"70","author":"Togashi","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2016.07.008_bib0045","first-page":"1025","article-title":"Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases","volume":"35","author":"Hata","year":"2015","journal-title":"Anticancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216304044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216304044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T17:37:38Z","timestamp":1568137058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216304044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":9,"alternative-id":["S0169500216304044"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.07.008","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}